Editorial for the Special Issue on Kynurenines in Neuropharmacology
Eds. Clarke, G., Stone, T. W., and Schwarcz, R
The Kynurenine Pathway: Towards Metabolic Equilibrium
Clarke, G., Stone, T. W., and Schwarcz, R.
Metabolism of tryptophan along the kynurenine pathway yields multiple metabolites that collectively exhibit both a rich pharmacology and a broad neurobiological significance (Schwarcz et al. 2012 ).This includes not just neurotoxic and neuroprotective metabolites that exert their influence via opposing action at NMDA receptors but also molecules with activity at metabotropic glutamate receptor subtypes, the aryl hydrocarbon receptor and specific Gprotein coupled receptors (GPCRs) (Stone et al. 2013) . Despite the therapeutic possibilities arising from this extensive pharmacological repertoire, kynurenines have struggled to reach a status in the scientific consciousness comparable with other tryptophan metabolites such as serotonin and melatonin. The growing realisation that the sphere of influence of dysregulated metabolism extends to most fundamental aspects of brain function with manifestations possible across the life span has seen this imbalance somewhat rectified. Now that these metabolites are no longer neglected, it is not surprising that altered metabolism along this pathway has been associated with numerous psychiatric and neurological disorders. Indeed, the immunoresponsive and stress-reactive nature of kynurenine pathway enzymes has stimulated biomarker studies and brought into focus a number of appealing therapeutic targets of relevance across a wide swathe of pathologies. The pathway still holds much unlocked potential and although there is now a solid grasp of many of its features and nuances, there remain understudied metabolites and enzymes as well as the capacity for ongoing research to reveal new layers of complexity and provide fresh insights.
This special issue of Neuropharmacology is an effort to provide a collection of articles to illustrate the research challenges and opportunities provided by our mounting but still incomplete knowledge of kynurenine pathway metabolism. Schwarcz As research advances in this area and moves beyond more general concepts of pathway activation, it is clear that certain metabolites of the kynurenine pathway may hold special relevance for specific disorders. For example, much research now associates the accumulation of quinolinic acid with Amyotrophic lateral sclerosis (ALS) (Lee et al. 2016 ).
In tandem, information about an expanding range of molecular targets continues to emerge for previously understudied metabolites including cinnabarinic acid as an orthosteric agonist of mGlu4 receptors and the activation of mGlu2 and mGlu3 receptors by xanthurenic acid Taken together, the breadth of these topics should make clear our motivation to put the kynurenine pathway under the spotlight in this special issue. The capacity of the kynurenines to surprise us should not be underestimated and we hope that the insights in this compilation of articles provides both stimulus and direction for ongoing research efforts and new researchers in the field. Now that consequences of the dysregulation of kynurenine pathway metabolism is more fully appreciated and as the range of activity of the kynurenines is further teased apart, we can start to envisage the benefits of interventions that move us back towards a metabolic equilibrium.
